Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings
- PMID: 36227005
- PMCID: PMC10102254
- DOI: 10.1097/MCG.0000000000001778
Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings
Abstract
Purpose: Fecal microbiota transplant (FMT) is increasingly performed for Clostridioides difficile infection (CDI), although long-term efficacy and safety data are limited and are focused on results from academic medical centers rather than private settings where most patients receive care.
Methods: Medical records of 165 patients who received FMTs for CDI were reviewed from an academic medical center and an adjacent, unaffiliated private practice. Of these patients, 68 also completed a survey regarding their long-term disease course and interval health.
Results: CDI resolution occurred in 81.3% (100/123) at the academic center and 95.2% (40/42) in the private setting. Private practice patients were more likely to present with recurrent, rather than refractory, CDI (92.9% vs. 66.7% P <0.001). Those from the academic center were more likely to have comorbid IBD, recent hospitalization, recent proton pump inhibitor use, ongoing immunosuppression, and inpatient FMT (all P values <0.05).Among surveyed patients, 29.4% developed interval comorbidities or changes to pre-existing conditions after a median follow-up of 33.7 months (IQR 13.2 to 44.3 mo). Of 30 patients requiring subsequent antibiotics, 13.3% suffered CDI relapse. All subjects who had initially responded to FMT but had a subsequent CDI (17.9%, 10/56) responded to another FMT.
Conclusions: In a real-world setting, patients who underwent FMT at academic centers differed significantly in clinical characteristics from those treated at a private practice. In both settings, FMT is an effective treatment for CDI not responding to standard therapies, even after subsequent antibiotic use. New diagnoses following FMT, however, are common and merit further exploration.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Hospitalized Older Patients with Clostridioides difficile Infection Refractory to Conventional Antibiotic Therapy Benefit from Fecal Microbiota Transplant.Adv Geriatr Med Res. 2021;3(2):e210012. doi: 10.20900/agmr20210012. Epub 2021 Apr 30. Adv Geriatr Med Res. 2021. PMID: 34263258 Free PMC article.
-
Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735. doi: 10.1007/s10096-019-03602-2. Epub 2019 Jun 5. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31165961
-
Fecal Microbiome Transplantation for Recurrent Clostridioides difficile Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series.J Gastrointestin Liver Dis. 2021 Dec 21;30(4):470-476. doi: 10.15403/jgld-3800. J Gastrointestin Liver Dis. 2021. PMID: 34752587
-
Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease : A Systematic Review and Meta-analysis.J Clin Gastroenterol. 2023 Mar 1;57(3):285-293. doi: 10.1097/MCG.0000000000001633. J Clin Gastroenterol. 2023. PMID: 34864789
-
Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.Dig Dis Sci. 2022 Mar;67(3):978-988. doi: 10.1007/s10620-021-06908-4. Epub 2021 Mar 22. Dig Dis Sci. 2022. PMID: 33748913
Cited by
-
The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome.Adv Sci (Weinh). 2023 Dec;10(35):e2301097. doi: 10.1002/advs.202301097. Epub 2023 Nov 1. Adv Sci (Weinh). 2023. PMID: 37914662 Free PMC article. Review.
-
Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi Consensus.J Gastroenterol Hepatol. 2025 Jun;40(6):1364-1373. doi: 10.1111/jgh.16947. Epub 2025 Mar 27. J Gastroenterol Hepatol. 2025. PMID: 40143713 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention. Healthcare-Associated Infections – Community Interface (HAIC). Clostridioides difficile infection (CDI) tracking.
-
- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1–e48. - PMC - PubMed
-
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources